CoreAge Rx vs Wellorithm
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Wellorithm head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 58 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make Wellorithm a bad call — it's best for readers who specifically want an oral dissolving tablet and will complete an intake before learning any cost. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Wellorithm | |
|---|---|---|
| Brief Score | 94/100 (A) | 58/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | Pricing not published |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | Pricing not published |
| Coverage | US only; restrictions by state, confirmed at intake | 49 states (not Louisiana) |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
Wellorithm: Nothing to track on the GLP-1s — those stay behind the quiz. Seven other products do publish rates, including brand pens at $1,119 a month.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.